Mirion (MIR) Q3 2026 earnings review
Mirion's nuclear orders double, but its profit margin target falls
Mirion, a maker of radiation detection gear for nuclear plants and hospitals, booked a wave of orders and began turning its backlog into sales. Orders excluding acquisitions jumped 62% as nuclear power demand more than doubled, and sales from businesses owned a year ago rose 6.5%. Chief executive Thomas Logan lifted the full-year sales and cash flow plans, though he expects mid-to-high teens underlying sales growth in the fourth quarter to get there.
| Sales from businesses owned a year ago | +6.5% +1.2% in Q2; planned for ~7–9% |
|---|---|
| Orders excluding acquisitions | $340M +62% from a year ago (nuclear +105%) |
| Free cash flow, excluding one-offs | $47M $107M year-to-date, doubled from 2025 |
| Full-year outlook | Mixed Sales and cash raised; profit margin cut |
⚖️ Verdict: 🟢 Bullish
The story got better because the long-awaited pickup in underlying sales finally started while nuclear orders accelerated again. Cash collections also beat expectations, allowing a $12.5 million raise to the middle of the full-year cash flow plan. The bad news: profit margins shrank slightly in Q3 instead of expanding as planned, forcing management to trim its full-year profit margin target and setting back its 2028 margin goal.
The question now is whether Mirion can deliver mid-to-high teens underlying sales growth and a nearly 30% profit margin in the fourth quarter. Either existing-reactor orders ship quickly at high margins, or project delays and lower-margin new-build equipment hold back both sales and profit as they did late last year. Fourth-quarter results will settle it.
🐂 Bull Case
Nuclear Orders Double and Lift the Sales Plan
Mirion sells radiation detection and safety gear, and its equipment sits in over 98% of the world's commercial nuclear reactors. Chief executive Thomas Logan said the company is "benefiting from today’s reinvestment in the existing nuclear reactor fleet", which supplies about 80% of its nuclear revenue. Customers also ordered gear for "large-scale new builds and small modular reactors", which are smaller, factory-built nuclear plants.
- Orders excluding acquisitions: $340 million, up 62% from a year ago
- Total orders including Paragon and Certrec: $386 million, up 85%
- Nuclear power orders: up 105% from a year ago
- Sales from businesses owned a year ago: up 6.5%, after 1.2% in Q2
This order growth matters because underlying sales had grown only 1% to 3% over the prior three quarters while backlog built up. Faster shipments in Q3 gave Logan the confidence to raise the full-year underlying sales growth plan from 5%–7% to 7%–8%.
What to watch: the nuclear power underlying sales growth rate in the conference call remarks and quarterly filing. A reading in the high single digits or better would show that existing-plant orders are turning into revenue inside the year.
Cash Flow Beats the Plan and Funds Buybacks
Cash generation has been a bright spot all year for the radiation-equipment maker. In the third quarter, free cash flow excluding one-offs reached $47 million, taking the nine-month total to $107 million, more than double last year's level. On a standard accounting basis, nine-month operating cash flow minus factory and equipment spending more than doubled to $105 million by our math.
Strong customer collections allowed Mirion to raise its full-year cash flow target by $12.5 million at the middle of the range, to $170–185 million. The company now expects to turn 60% to 63% of its Adjusted EBITDA (profit before interest, tax, depreciation, and one-offs) into cash, up from 54% to 58% previously.
What to watch: fourth-quarter customer collections and inventory levels. By our math, the new outlook requires about $70.5 million of cash flow in Q4, which is down from $78 million in the fourth quarter of last year.
Positives this quarter didn't test
Two internal initiatives from prior quarters had no updated figures in the earnings release.
- Artificial intelligence software tools (including PlanAI and Daily QA 4 Pro for medical radiation therapy): not detailed in the release; the call remarks will show whether customer adoption is growing.
- Management's organisational restructuring to reduce management layers: non-operating expenses fell to $3.1 million from $5.4 million a year ago, and the quarterly filing will show the exact severance charges and 2027 savings plan.
🐻 Bear Case
Higher Sales Come With a Lower Margin Target
"We are updating our guidance to reflect increased visibility to full year performance," Logan said. While the sales outlook went up, the profit outlook went down. Mirion cut the top end of its full-year Adjusted EBITDA plan by $8 million, to $285–292 million, and lowered its full-year margin target from 25.0%–26.0% to 24.7%–25.2%.
The squeeze started in the third quarter. Management had planned for Q3 Adjusted EBITDA margin to expand from last year's 23.5%, but it shrank by 0.2 percentage points to 23.3%. Stock-based pay rose by 0.6 percentage points of revenue to 2.6%, and product cost of sales rose to 55.3% of product revenue from 53.9% a year ago, offsetting a 1.4-point improvement in service costs.
This cut makes Mirion's longer-term goal of a 30% Adjusted EBITDA margin by 2028 harder to reach. At the middle of the new 2026 range (24.95%), the margin improves by just 0.35 percentage points over 2025, leaving more than 2.5 points of annual improvement needed in both 2027 and 2028.
What to watch: fourth-quarter Adjusted EBITDA margin. By our math, hitting the middle of the full-year plan still requires a 29.8% margin in Q4, up from 28.0% a year ago, so any further mix shift toward lower-margin equipment would cause a miss.
The Fourth Quarter Still Needs Steep Growth
Logan said third-quarter results showed "an inflection in organic revenue growth" as sales from businesses owned a year ago rose 6.5%, up from 1.2% in Q2. However, management's prior plan called for high-single-digit growth (about 7% to 9%) in Q3, so the quarter fell slightly short of its own benchmark.
Because the full-year underlying growth target was raised to 7%–8%, the fourth quarter still carries a heavy load. Mirion said it expects "mid-to-high teens growth in the fourth quarter" (about 15% to 18%). That is a big jump from 6.5% in Q3, and last year the company missed its fourth-quarter underlying sales target when project deliveries slipped.
What to watch: fourth-quarter underlying sales growth against the mid-to-high teens plan. Because large nuclear orders take 18 months or more to turn into revenue, Q4 depends on shipping existing backlog and short-cycle orders before December 31.
Buybacks and Shares Keep Debt and Dilution High
Mirion financed last year's Paragon acquisition with convertible debt and new shares, which pushed its diluted share count up 6.7% from a year ago to 272.9 million. Because of the extra shares and a decision to include $7.1 million of stock-based pay as an expense in 2026, profit per share excluding one-offs stayed flat at $0.12 despite a 24.5% rise in revenue.
To offset the share count, the company spent $55.8 million buying back stock in Q3 by our math, bringing nine-month buybacks to $96.8 million. Because cash went to buybacks instead of debt reduction, Logan now expects to "reduce net leverage to approximately 2.6x by year-end", slightly worse than last quarter's target of under 2.5x.
What to watch: net debt at year-end, which stood at $792.9 million in Q3 by our math. If cash goes to further buybacks or deals in Q4, debt relative to profit will stay above the 2.6x plan.
Risks this quarter didn't answer
Four standing concerns from prior quarters could not be checked because the earnings release did not include segment or backlog tables.
- Total backlog at quarter-end: not printed in the release; the quarterly filing's backlog note will show how much the $386 million of Q3 orders added to the $1.14 billion Q2 backlog.
- Medical segment sales and margins: not broken out in the release; the presentation and filing will show if dosimetry and nuclear medicine recovered.
- Russia and China backlog risk ($124 million at Q2 after an $18 million Chinese cancellation): awaits the geographic note in the quarterly filing.
- Large project pipeline awards (12 projects worth about $280 million at Q2): awaits management's update on the conference call.
💲 Other KPIs
Total sales rose 24.5% from a year ago, up from 19.7% growth in Q2, helped by the Paragon and Certrec acquisitions. Physical product sales grew 28.5% to $213.5 million, while service revenue grew 12.8% to $64.3 million. Gross margin across both lines edged up 0.5 percentage points to 47.3%.
Operating profit more than doubled from $7.4 million a year ago, lifting the operating margin by 2.9 percentage points to 6.2%. Selling, general, and administrative overhead fell by 1.6 percentage points of revenue to 37.4% by our math, and research and development spending fell by 0.8 points to 3.7%, offsetting higher intangible amortisation from acquisitions.
Deferred contract revenue — upfront payments from customers for work Mirion has not yet delivered — rose 8.5% from $112.3 million at the end of 2025 and 2.9% from $118.4 million in Q2. The steady rise alongside $97.6 million of unbilled contract work shows active project execution ahead of the fourth quarter.
🔮 Guidance
Raised. The middle of the underlying sales growth plan moved up 1.5 percentage points to 7.5% after sitting unchanged for two quarters. Management explicitly plans for mid-to-high teens growth (15% to 18%) in the fourth quarter to reach this target, up from 6.5% in Q3.
Raised. The middle of the range rose 1.5 percentage points to 24.5%, which includes foreign exchange and the Paragon and Certrec acquisitions. By our math, that implies fourth-quarter revenue of about $350 million, or 26.1% growth from a year ago, before Paragon laps its December acquisition date.
Cut. The top end of the profit range fell by $8 million, and the middle of the margin plan dropped by 0.55 percentage points to 24.95%. By our math, the middle of the new range still leaves $104.1 million of Adjusted EBITDA for Q4, up 34% from a year ago at a 29.8% margin.
Raised. The middle of the cash flow plan increased by $12.5 million to $177.5 million, and the share of profit turning into cash rose by 5.5 percentage points to 61.5%. With $107 million already collected in the first nine months, the plan leaves $70.5 million for Q4 by our math, down from $78 million in Q4 last year.
Raised slightly at the middle of the range. Narrowing the band lifted the middle by half a cent to $0.52, or 13% growth from $0.46 in 2025. After delivering $0.34 across the first three quarters, the outlook leaves $0.18 per share for Q4 by our math, up from $0.15 in the fourth quarter of last year.
❓ Key Questions
Why did Q3 profit margins shrink despite faster sales?
Management planned for Q3 Adjusted EBITDA margin to expand from last year's 23.5%, but it slipped to 23.3%, and the full-year margin plan was cut by 0.55 points. Investors need to know how much came from lower-margin nuclear projects versus Paragon integration costs.
What is the total backlog after Q3's $386M order intake?
The earnings release did not print quarter-end backlog, which stood at $1.14 billion in Q2. Knowing the exact backlog figure and whether any further Chinese or Russian orders were cancelled is essential to check the quality of the order book.
How did the Medical division perform in the third quarter?
The release gave no segment table after Medical underlying sales shrank 0.9% in Q2 and management cut its full-year targets for nuclear medicine and dosimetry. Investors need the segment split to see if Medical is still dragging on company margins.
How much of Q4's mid-to-high teens growth is already in backlog?
Reaching 15% to 18% underlying sales growth in Q4 is a big step up from 6.5% in Q3. Management should specify how much of Q4 revenue is covered by scheduled backlog shipments versus orders that must be won and shipped inside the quarter.